Monocyclic CGRP receptor antagonists

Details for Australian Patent Application No. 2009228453 (hide)

Owner Merck Sharp & Dohme Corp.

Inventors Zartman, C. Blair; Selnick, Harold G.; Stachel, Shawn J.; Steele, Thomas; Bell, Ian M.; Staas, Donnette D.; McWherter, Melody; Stump, Craig; Wood, Michael R.

Agent Spruson & Ferguson

Pub. Number AU-A-2009228453

PCT Pub. Number WO2009/120652

Priority 61/072,236 28.03.08 US

Filing date 24 March 2009

Wipo publication date 1 October 2009

International Classifications

C07D 211/00 (2006.01) Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings

A61K 31/44 (2006.01) - Non-condensed pyridines

A61K 31/54 (2006.01) - having six-membered rings with at least one nitrogen and at least one sulfur as the ring hetero atoms, e.g. sulthiame

C07D 487/00 (2006.01) Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups

Event Publications

2 September 2010 PCT application entered the National Phase

  PCT publication WO2009/120652 Priority application(s): WO2009/120652

3 May 2012 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(a). A direction to request examination has been given for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2009228463-Method and apparatus for resource management in a wireless communica- tion system

2009228451-Aromatic heterocyclic fused indolobenzadiazepine HCV NS5B inhibitors